(EMAILWIRE.COM, May 25, 2019 ) According to research the global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=152603894
Based on route of administration, the vaccine adjuvants market includes oral route, subcutaneous route, intranasal route, intramuscular route, intradermal route, and other routes.
Based on disease type, the vaccine adjuvants market comprises of infectious diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global market in 2016.
Based on applications, the vaccine adjuvants market is segmented into research applications and commercial applications. The research applications segment is expected to account for the largest share of the market during the forecast period.
Based on application categories, the vaccine adjuvants market is segmented into human and veterinary adjuvants. The human vaccine adjuvants segment is expected to account for the largest share of the global market in 2016 and is expected to have a higher growth rate in the application category segment.
The vaccine adjuvants market is consolidated in nature due to the presence of a few large players. Prominent players in the vaccine adjuvants market include Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc., and OZ Biosciences (France).
SEPPIC (France) held the second position in the vaccine adjuvants market in 2015. This can be attributed to the company’s strong portfolio of vaccine adjuvants. The company adopts organic growth strategies such as expansions to boost its market share. For instance, SEPPIC (France) launched a production and sterile packaging unit for vaccine adjuvants and injectables by investing USD 6.66 million in Castres, France.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894
Brenntag Biosector (Denmark) was the global leader in the vaccine adjuvants market in 2015. The company is a subsidiary of Brenntag AG (Germany). It is a well-known company and has an exhaustive product portfolio. The company is innovation-centric and invests heavily in R&D for maintaining its market share. The company also focuses on inorganic growth strategies such as agreements to enhance its market share.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
newsletter@marketsandmarkets.com